RBC Capital raised the firm’s price target on Boston Scientific to $95 from $85 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results. The firm’s industry checks suggest that Q3 underlying utilization trends were positive despite typical summer seasonality driving a sequential step-down in elective procedures, the analyst tells investors in a research note. Investor sentiment is also positive for MedTech stocks going into the earnings season, and investors are likely to continue to chase winners and catalyst-driven names into year-end, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific put volume heavy and directionally bearish
- Boston Scientific target raised, added to ‘Tactical Outperform’ list at Evercore
- Boston Scientific receives PMDA approval in Japan for FARAPULSE PFA System
- Boston Scientific closes acquisition of Silk Road Medical
- Boston Scientific: FDA approves expanded indication of INGEVITY+ Pacing Leads
Questions or Comments about the article? Write to editor@tipranks.com